# WAKIX® (pitolisant) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pitolisant

> The PDUFA target action date for WAKIX® (pitolisant), sponsored by Harmony Biosciences Holdings, Inc. (HRMY), is Q1 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, year only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the WAKIX® (pitolisant) PDUFA date?

The PDUFA target action date for WAKIX® (pitolisant), sponsored by Harmony Biosciences Holdings, Inc. (HRMY), is Q1 2027. Status: scheduled. Press release filed with the SEC (EX-99): "NDA submission in Q2 2026; anticipated PDUFA date in Q1 2027 o Approximately 80-90% of patients with narcolepsy experience GI symptoms; pitolisant GR is designed to minimize the worsening of these symptoms o Ability to initiate treatment at therapeutic dose with no titration" Last confirmed May 7, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/pitolisant)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-018858, https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224xex99d1.htm (retrieved 2026-11-12). Last confirmed 2026-05-07. Cite: https://sec-api.dev/pdufa/pitolisant#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | WAKIX® (pitolisant) |
| Codes |  |
| Sponsor | Harmony Biosciences Holdings, Inc. (HRMY) https://sec-api.dev/companies/hrmy/catalysts |
| Indications | eds in pediatric patients six years of age and older with narcolepsy, [lennox-gastaut syndrome](https://sec-api.dev/indications/lennox-gastaut-syndrome), [lennox- gastaut syndrome](https://sec-api.dev/indications/lennox-gastaut-syndrome) |
| Modality |  |
| FDA designations | fast track, orphan, priority review |

## Timeline

### August 14, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211150 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190814, review_priority PRIORITY; sponsor_name HARMONY; product WAKIX (PITOLISANT HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211150%22

### October 13, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211150 ORIG-2 (Efficacy): submission_status AP, submission_status_date 20201013, review_priority PRIORITY; sponsor_name HARMONY; product WAKIX (PITOLISANT HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211150%22

### Apr 2022: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-02-25, last confirmed 2025-02-25.
- SEC Form 10-K (accession 0001558370-25-001441): "In April 2022, we initiated a Phase 3 registrational trial, the INTUNE Study, to evaluate the efficacy and safety of pitolisant in adult patients with IH." https://www.sec.gov/Archives/edgar/data/1802665/000155837025001441/hrmy-20241231x10k.htm

### Nov 2022: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-02-25, last confirmed 2025-02-25.
- SEC Form 10-K (accession 0001558370-25-001441): "Topline results from this clinical proof-of-concept trial were reported in November 2022 and showed a positive signal on improvement in the primary outcome related to EDS." https://www.sec.gov/Archives/edgar/data/1802665/000155837025001441/hrmy-20241231x10k.htm

### June 21, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact. Indication: EDS in pediatric patients six years of age and older with narcolepsy.
- First seen 2025-02-25, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211150 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20240621, review_priority PRIORITY; sponsor_name HARMONY; product WAKIX (PITOLISANT HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211150%22
- SEC Form 10-Q (accession 0001104659-26-056720): "In June 2024, we announced that the FDA approved our sNDA for WAKIX for the treatment of EDS in pediatric patients six years of age and older with narcolepsy." https://www.sec.gov/Archives/edgar/data/1802665/000110465926056720/hrmy-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-018859): "In June 2024, we announced that the FDA approved our sNDA for WAKIX for the treatment of EDS in pediatric patients six years of age and older with narcolepsy." https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/hrmy-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-105962): "In June 2024, we announced that the FDA approved our sNDA for WAKIX for the treatment of EDS in pediatric patients six years of age and older with narcolepsy." https://www.sec.gov/Archives/edgar/data/1802665/000110465925105962/hrmy-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010185): "In June 2024, we announced that the FDA approved our sNDA for WAKIX for the treatment of EDS in pediatric patients six years of age and older with narcolepsy." https://www.sec.gov/Archives/edgar/data/1802665/000155837025010185/hrmy-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006394): "In June 2024, we announced that the FDA approved our sNDA for WAKIX for the treatment of EDS in pediatric patients six years of age and older with narcolepsy." https://www.sec.gov/Archives/edgar/data/1802665/000155837025006394/hrmy-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001441): "In June 2024, we announced that the FDA approved our sNDA for WAKIX for the treatment of EDS in pediatric patients six years of age and older with narcolepsy." https://www.sec.gov/Archives/edgar/data/1802665/000155837025001441/hrmy-20241231x10k.htm

### 2025: NDA/BLA submission

- Status: scheduled. Date confidence: year.
- First seen 2025-05-06, last confirmed 2025-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105942): "All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2025 net product revenue, expectations for the growth and value of WAKIX, plans to submit an sNDA for pitolisant in idiopathic hypersomnia; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products." https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/hrmy-20251104xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-101688): "All statements contained in this press release that do not relate to matters of historical fact should be considered forward- looking statements, including statements regarding our full year 2025 revenue, expectations for the growth and value of WAKIX, plans to submit an sNDA for pitolisant in idiopathic hypersomnia; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products." https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010182): "All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2025 net product revenue, expectations for the growth and value of WAKIX, plans to submit an sNDA for pitolisant in idiopathic hypersomnia; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products." https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-008415): "All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2025 net product revenue, expectations for the growth and value of WAKIX, plans to submit an sNDA for pitolisant in idiopathic hypersomnia; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products." https://www.sec.gov/Archives/edgar/data/1802665/000155837025008415/hrmy-20250605xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-006393): "All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2025 net product revenue, expectations for the growth and value of WAKIX, plans to submit an sNDA for pitolisant in idiopathic hypersomnia; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products." https://www.sec.gov/Archives/edgar/data/1802665/000155837025006393/hrmy-20250506xex99d1.htm

### Q3 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-01-13, last confirmed 2025-05-06.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-001439): "Pivotal bioequivalence study on track to initiate Q1 2025 o Topline data readout anticipated in Q3 2025 with potential PDUFA in 2026" https://www.sec.gov/Archives/edgar/data/1802665/000155837025001439/hrmy-20250225xex99d1.htm
- SEC Form 10-Q (accession 0001558370-25-006394): "We initiated the pivotal bioequivalence study in the first quarter of 2025 and anticipate the topline data readout in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1802665/000155837025006394/hrmy-20250331x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-000157): "◾ EPX-100 is the most advanced 5HT2 (serotonin) agonist in clinical development o Initiation of Pitolisant-GR pivotal bioequivalence study in Q1 2025 with readout anticipated Q3 2025" https://www.sec.gov/Archives/edgar/data/1802665/000155837025000157/hrmy-20250113xex99d1.htm
- SEC Form 10-K (accession 0001558370-25-001441): "We are on-track to initiate a pivotal bioequivalence study in the first quarter of 2025, with an anticipated data readout in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1802665/000155837025001441/hrmy-20241231x10k.htm

### Q4 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-08-05, last confirmed 2025-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105942): "Pitolisant HD IND submitted; On Track to Initiate Phase 3 Trials in Narcolepsy and Idiopathic Hypersomnia in Q4 2025" https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/hrmy-20251104xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010182): "Initiation of Next-Generation Pitolisant HD Phase 3 Registrational Trials in Narcolepsy & Idiopathic Hypersomnia in Q4 2025; Both Indications Targeted for PDUFA in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805xex99d1.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-08-05, last confirmed 2025-11-04.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010182): "Topline data readout from pivotal BE study anticipated in Q4 2025 with potential PDUFA date in 2026." https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805xex99d1.htm
- SEC Form 10-Q (accession 0001104659-25-105962): "We initiated the pivotal bioequivalence study in the first quarter of 2025 and anticipate the topline data readout in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1802665/000110465925105962/hrmy-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010185): "We initiated the pivotal bioequivalence study in the first quarter of 2025 and anticipate the topline data readout in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1802665/000155837025010185/hrmy-20250630x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105942): "Topline data readout from pivotal bioequivalence study on track for Q4 2025" https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/hrmy-20251104xex99d1.htm

### Nov 2025: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2026-02-24, last confirmed 2026-02-24.
- SEC Form 10-K (accession 0001104659-26-018859): "We initiated the pivotal bioequivalence study in the first quarter of 2025 and announced positive topline data in November 2025." https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/hrmy-20251231x10k.htm

### February 13, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211150 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260213, review_priority PRIORITY; sponsor_name HARMONY; product WAKIX (PITOLISANT HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211150%22

### Q2 2026: PDUFA date

- Status: scheduled. Date confidence: quarter.
- First seen 2025-02-25, last confirmed 2026-05-07.
- SEC Form 10-Q (accession 0001558370-25-010185): "Our anticipated PDUFA date for Pitolisant GR is in 2026." https://www.sec.gov/Archives/edgar/data/1802665/000155837025010185/hrmy-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006394): "Our anticipated PDUFA date for Pitolisant GR is in 2026." https://www.sec.gov/Archives/edgar/data/1802665/000155837025006394/hrmy-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001441): "Our anticipated PDUFA date for pitolisant GR is in 2026." https://www.sec.gov/Archives/edgar/data/1802665/000155837025001441/hrmy-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056786): "PITOLISANT GR - NDA SUBMISSION 2Q26, PDUFA DATE" https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d2.htm

### Q2 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-01-12, last confirmed 2026-02-24.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-018858): "NDA submission in Q2 2026; anticipated PDUFA date in Q1 2027 o Approximately 80-90% of patients with narcolepsy experience GI symptoms; pitolisant GR is designed to minimize the worsening of these symptoms o Ability to initiate treatment at therapeutic dose with no titration" https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224xex99d1.htm
- SEC Form 10-K (accession 0001104659-26-018859): "With positive findings from both the pivotal bioequivalence and dosing optimization studies, we are on track to submit a New Drug Application ("NDA") for Pitolisant GR in early 2026 with a target PDUFA date in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/hrmy-20251231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-002731): "NDA submission in 2Q 2026; anticipated PDUFA date in 1Q 2027" https://www.sec.gov/Archives/edgar/data/1802665/000110465926002731/hrmy-20260112xex99d1.htm

### Jun 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-08-04, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001104659-26-122390): "In June 2026, we submitted a New Drug Application ("NDA") for Pitolisant GR to the FDA, which was subsequently accepted for full review with a target Prescription Drug User Fee Act ("PDUFA") date of April 1, 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-122390): "In June 2026, we submitted an NDA for Pitolisant GR to the FDA, which was subsequently accepted for full review with a target PDUFA date of April 1, 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-090090): "In June 2026, we submitted a New Drug Application ("NDA") for Pitolisant GR to the FDA, which was subsequently accepted for full review with a target Prescription Drug User Fee Act ("PDUFA") date of April 1, 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/hrmy-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-090090): "In June 2026, we submitted an NDA for Pitolisant GR to the FDA, which was subsequently accepted for full review with a target PDUFA date of April 1, 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/hrmy-20260630x10q.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-05-07, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056786): "o Phase 3 topline data readout expected in 2H 2026 o Supports Pediatric Exclusivity for WAKIX: Fulfills a key regulatory requirement for six months of additional regulatory exclusivity, extending exclusivity to March 2030" https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d1.htm

### Q1 2027: PDUFA date

- Status: scheduled. Date confidence: quarter.
- First seen 2025-11-04, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-018858): "NDA submission in Q2 2026; anticipated PDUFA date in Q1 2027 o Approximately 80-90% of patients with narcolepsy experience GI symptoms; pitolisant GR is designed to minimize the worsening of these symptoms o Ability to initiate treatment at therapeutic dose with no titration" https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-056720): "We are on track to submit an NDA in the second quarter of 2026 and anticipate a PDUFA date for Pitolisant GR in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926056720/hrmy-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-018859): "With positive findings from both the pivotal bioequivalence and dosing optimization studies, we are on track to submit a New Drug Application ("NDA") for Pitolisant GR in early 2026 with a target PDUFA date in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/hrmy-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-018859): "We anticipate a PDUFA date for Pitolisant GR in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/hrmy-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-105962): "We anticipate a PDUFA date for Pitolisant GR in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465925105962/hrmy-20250930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-002731): "NDA submission in 2Q 2026; anticipated PDUFA date in 1Q 2027" https://www.sec.gov/Archives/edgar/data/1802665/000110465926002731/hrmy-20260112xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-002731): "PITOLISANT GR (ANTICIPATED PDUFA DATE Q1 2027)" https://www.sec.gov/Archives/edgar/data/1802665/000110465926002731/hrmy-20260112xex99d2.htm

### April 1, 2027: NDA/BLA acceptance

- Status: scheduled. Date confidence: exact.
- First seen 2026-08-04, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "NDA accepted by FDA in July; target PDUFA date of April 1, 2027 o Designed with enteric coating meant to reduce the potential for GI side effects in patients with narcolepsy, 80 - 90% of whom experience GI symptoms as part of their disease o Enables patients to initiate treatment at a therapeutic dose without titration, an important clinical differentiation" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm

### April 1, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Stage: 3.
- First seen 2026-08-04, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122377): "Pitolisant GR NDA Under FDA Review, PDUFA Date April 1, 2027; Pitolisant HD Phase 3 Topline Data in 2027, Target PDUFA Date in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "Pitolisant GR NDA Accepted in July; Target PDUFA Date April 1, 2027" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-122390): "In June 2026, we submitted a New Drug Application ("NDA") for Pitolisant GR to the FDA, which was subsequently accepted for full review with a target Prescription Drug User Fee Act ("PDUFA") date of April 1, 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-122390): "In June 2026, we submitted an NDA for Pitolisant GR to the FDA, which was subsequently accepted for full review with a target PDUFA date of April 1, 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-090090): "In June 2026, we submitted a New Drug Application ("NDA") for Pitolisant GR to the FDA, which was subsequently accepted for full review with a target Prescription Drug User Fee Act ("PDUFA") date of April 1, 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/hrmy-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-090090): "In June 2026, we submitted an NDA for Pitolisant GR to the FDA, which was subsequently accepted for full review with a target PDUFA date of April 1, 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/hrmy-20260630x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122377): "NDA accepted by the FDA with PDUFA date of April 1, 2027 o Enables patients to initiate treatment at a therapeutic dose without titration, an important clinical differentiation" https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "NDA accepted by FDA in July; target PDUFA date of April 1, 2027 o Designed with enteric coating meant to reduce the potential for GI side effects in patients with narcolepsy, 80 - 90% of whom experience GI symptoms as part of their disease o Enables patients to initiate treatment at a therapeutic dose without titration, an important clinical differentiation" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-122390): "In June 2026, a New Drug Application ("NDA") for Pitolisant GR was submitted to the FDA, which was subsequently accepted for full review with a target Prescription Drug User Fee Act date of April 1, 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "PDUFA date anticipated April 1, 2027" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d2.htm

### mid-2027: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3. Indication: Lennox- Gastaut syndrome.
- First seen 2026-01-12, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122377): "Topline data expected in mid-2027 and anticipated PDUFA date in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "Topline data expected in mid-2027 and anticipated PDUFA date in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm
- SEC Form 10-K (accession 0001104659-26-018859): "We anticipate topline data from both studies in 2027 and a potential PDUFA date for the Pitolisant HD narcolepsy and IH programs in 2028." https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/hrmy-20251231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-018858): "o Topline data in 2027; anticipated PDUFA date in 2028 o Enhanced formulation with optimized PK profile, GR coating and higher dose to drive greater efficacy o Differentiated indications: fatigue in narcolepsy and sleep inertia in IH" https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-002731): "§Topline data in 2027; anticipated PDUFA date in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926002731/hrmy-20260112xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-122390): "We expect topline data in 2027 and anticipate a target PDUFA date in 2028." https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-090090): "We expect topline data in 2027 and anticipate a target PDUFA date in 2028." https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/hrmy-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-056720): "We anticipate topline data in 2027 and a potential PDUFA date in 2028." https://www.sec.gov/Archives/edgar/data/1802665/000110465926056720/hrmy-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-018859): "We anticipate topline data from both studies in 2027 and a potential PDUFA date in 2028." https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/hrmy-20251231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "Topline data expected in 1H 2027 and anticipated PDUFA dates in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056786): "Topline data anticipated 1H 2027" https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d2.htm
- SEC Form 10-Q (accession 0001104659-26-122390): "We anticipate topline data from the TEMPO study in mid-2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm

### 2028: PDUFA date

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2025-02-25, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "Pitolisant HD On Track for Phase 3 Topline Data in 2027 and Target PDUFA Date in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010182): "Initiation of Next-Generation Pitolisant HD Phase 3 Registrational Trials in Narcolepsy & Idiopathic Hypersomnia in Q4 2025; Both Indications Targeted for PDUFA in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805xex99d1.htm
- SEC Form 10-Q (accession 0001104659-25-105962): "We anticipate a PDUFA date for the Pitolisant HD narcolepsy and IH programs in 2028." https://www.sec.gov/Archives/edgar/data/1802665/000110465925105962/hrmy-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010185): "Our anticipated PDUFA date for the Pitolisant HD narcolepsy and IH programs is in 2028." https://www.sec.gov/Archives/edgar/data/1802665/000155837025010185/hrmy-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006394): "Our anticipated PDUFA date for the Pitolisant HD narcolepsy and IH programs is in 2028." https://www.sec.gov/Archives/edgar/data/1802665/000155837025006394/hrmy-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001441): "Our anticipated PDUFA date for pitolisant HD is in 2028." https://www.sec.gov/Archives/edgar/data/1802665/000155837025001441/hrmy-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001441): "Our anticipated PDUFA date for the pitolisant HD narcolepsy and IH programs is in 2028." https://www.sec.gov/Archives/edgar/data/1802665/000155837025001441/hrmy-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122377): "Topline data expected in mid-2027 and anticipated PDUFA date in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "Topline data expected in mid-2027 and anticipated PDUFA date in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010182): "Phase 3 registrational trials in both narcolepsy and IH to initiate in Q4 2025 with target PDUFA dates in 2028." https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-018858): "o Topline data in 2027; anticipated PDUFA date in 2028 o Enhanced formulation with optimized PK profile, GR coating and higher dose to drive greater efficacy o Differentiated indications: fatigue in narcolepsy and sleep inertia in IH" https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-002731): "§Topline data in 2027; anticipated PDUFA date in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926002731/hrmy-20260112xex99d1.htm

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pitolisant.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "WAKIX® (pitolisant) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pitolisant

```bibtex
@misc{secapidev_pdufa_pitolisant_20261116,
  title        = {WAKIX® (pitolisant) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pitolisant}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pitolisant_20261116","title":"WAKIX® (pitolisant) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pitolisant","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
